Deoxyadenosine

Deoxyadenosine

SCHEMBL5182039

Nc1ncnc2c1ncn2[C@@H]1C[C@H](O)[C@@H](CO)O1

nearest known ligand 0.71

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HIF1A Q16665 1/20 0.71
▸ SMN1; SMN2 Q16637 2/20 0.70
▸ PNP P00491 1/20 0.70
▸ LMNA P02545 1/20 0.70
▸ TP53 P04637 1/20 0.70
▸ HTT P42858 1/20 0.70
▸ PDE4D Q08499 1/20 0.70
▸ PDE3A Q14432 1/20 0.70
▸ RXFP1 Q9HBX9 1/20 0.70
▸ ADORA3 P0DMS8 3/20 0.63
▸ DPP4 P27487 1/20 0.63
▸ MEN1 O00255 1/20 0.63
▸ SLC28A1 O00337 1/20 0.63
▸ MAP3K7 O43318 1/20 0.63
▸ SLC28A2 O43868 1/20 0.63
▸ GAPDH P04406 1/20 0.63
▸ MAPK1 P28482 1/20 0.63
▸ ADORA2A P29274 1/20 0.63
▸ ADORA2B P29275 1/20 0.63
▸ ADORA1 P30542 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Deoxyadenosine SCHEMBL5982298 1.00 HIF1A (0.71) HIF1ASMN1; SMN2PNPLMNATP53
Deoxyadenosine SCHEMBL19877 1.00 HIF1A (0.71) HIF1ASMN1; SMN2PNPLMNATP53
Deoxyadenosine SCHEMBL5982291 1.00 HIF1A (0.71) HIF1ASMN1; SMN2PNPLMNATP53
Deoxyadenosine SCHEMBL12222478 1.00 HIF1A (0.71) HIF1ASMN1; SMN2PNPLMNATP53
Deoxyadenosine SCHEMBL193181 1.00 HIF1A (0.71) HIF1ASMN1; SMN2PNPLMNATP53
Deoxyadenosine SCHEMBL23982174 1.00 HIF1A (0.71) HIF1ASMN1; SMN2PNPLMNATP53
Deoxyadenosine SCHEMBL532825 1.00 HIF1A (0.71) HIF1ASMN1; SMN2PNPLMNATP53
Deoxyadenosine SCHEMBL593935 1.00 HIF1A (0.71) HIF1ASMN1; SMN2PNPLMNATP53
Deoxyadenosine SCHEMBL21637036 1.00 HIF1A (0.71) HIF1ASMN1; SMN2PNPLMNATP53
Deoxyadenosine SCHEMBL12222447 1.00 HIF1A (0.71) HIF1ASMN1; SMN2PNPLMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0350292-B1 Process for preparing 2'-deoxy-beta-adenosine JAPAN TOBACCO INC (JP) 1994-05-04 — — EP claimed
US-5262531-A Process for preparing 2'-deoxy-β-adenosine JAPAN TOBACCO, INC. (JP) 1993-11-16 — — US claimed
EP-0350292-A2 Process for preparing 2'-deoxy-beta-adenosine Japan Tobacco Inc. (JP) 1990-01-10 — — EP claimed
JP-2017199-A — — None — — JP disclosed
EP-1554298-A4 PROCESS FOR THE PREPARATION OF 9-BETA-ANOMERIC NUCLEOSIDE ANALOGS ASH STEVENS INC (US) 2007-09-26 — — EP disclosed
EP-1554298-A1 PROCESS FOR THE PREPARATION OF 9-BETA-ANOMERIC NUCLEOSIDE ANALOGS ASH STEVENS, INC. (US) 2005-07-20 — — EP disclosed
US-6884880-B2 Process for the preparation of 9-β-anomeric nucleoside analogs ASH STEVENS, INC. (US) 2005-04-26 — — US disclosed
WO-2004018490-A1 PROCESS FOR THE PREPARATION OF 9-BETA-ANOMERIC NUCLEOSIDE ANALOGS ASH STEVENS, INC. (US) 2004-03-04 — — WO disclosed
US-20040039190-A1 Process for the preparation of 9-beta-anomeric nucleoside analogs ASH STEVENS, INC. 2004-02-26 — — US disclosed
EP-0350292-B1 Process for preparing 2'-deoxy-beta-adenosine JAPAN TOBACCO INC (JP) 1994-05-04 — — EP disclosed
US-5262531-A Process for preparing 2'-deoxy-β-adenosine JAPAN TOBACCO, INC. (JP) 1993-11-16 — — US disclosed
JP-H0217199-A PRODUCTION OF 2'-DEOXY-BETA-ADENOSINE JAPAN TOBACCO INC 1990-01-22 — — JP disclosed
EP-0350292-A2 Process for preparing 2'-deoxy-beta-adenosine Japan Tobacco Inc. (JP) 1990-01-10 — — EP disclosed
US-4760137-A Method for the production of 2'-deoxyadenosine compounds BRIGHAM YOUNG UNIVERSITY (US) 1988-07-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040039190-A1 Process for the preparation of 9-beta-anomeric nucleoside analogs DPYD, SLC29A2, GALE HIF1A 1549/4885SMN1; SMN2 1155/4885PNP 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback